This page is part of our 2024 average annual return archive: it shows the CRDF stock yearly return for calendar year 2024. This metric helps investors evaluate and compare performance among different stocks, over time.
Average annual return should be reviewed alongside overall market trends, and company fundamentals like earnings and revenue. As the saying goes on Wall St., past performance from 2024 does not guarantee future similar returns.
| CRDF Stock Yearly Return 2024 Table | ||||||||||||||||||||||||||||||
CRDF average annual return is presented with the assumption of reinvestments of any dividends on ex-date. |
| Average Annual Return Benchmarks |
|
Compare CRDF average annual return versus benchmarks: S&P Average Annual Return Dow Average Annual Return Nasdaq 100 Average Annual Return Russell 2000 Average Annual Return Gold Average Annual Return 10 Year Treasury Average Annual Return |
| CRDF Share Performance |
| CRDF Stock Yearly Return 2024 Chart | |||
Also see: • CRDF YTD return • CRDF average annual return 10 years | |||
| About Cardiff Oncology Inc |
| Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. The CRDF stock yearly return is shown above.
The yearly return on the CRDF stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2024 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon. One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the CRDF annual return calculation with any dividends reinvested as applicable (on ex-dates). |
| CRDF Current Stock Quote |
 Free CRDF Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Don't Forget Dividends in Annual Return! | |
|
| Yearly Return Peers |
| Cardiff Oncology (CRDF) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:
CRGX Average Annual Return |
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.3%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.3%.
Video: Don't Forget Dividends in Average Annual Return!